Is Semaglutide with cagrilintide legal in Canada?

The rare blend whose combination has actually been trialled, at scale: co-administered cagrilintide and semaglutide produced 20.4% mean weight loss at week 68 against 3.0% on placebo in 3,417 participants. What research vendors sell under this description is not that product, at that ratio, from that supply chain, and gastrointestinal adverse events affected 79.6% of the combination group in the trial.

This page has to do two jobs at once, and keeping them separate is the whole point. First job: the combination is real and it works.

Mechanism: Semaglutide agonises the GLP-1 receptor. Cagrilintide is a long-acting amylin analogue acting on satiety through amylin receptor signalling in the hindbrain.

Regulatory history: The co-formulated combination has been trialled at phase 3 and is the subject of regulatory filings. A research chemical blend sold under its description is not that product and is not approved.

Authorises drugs for sale through a Notice of Compliance and Drug Identification Number. A compound that is not authorised for sale cannot lawfully be sold for human use, and personal importation of prescription drugs is limited.

The classification above is the The Longevity Archive reading of Health Canada, Health Products and Food Branch listings for Semaglutide with cagrilintide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.